Company intelligence / Profile preview
Nobelpharma Co., Ltd.
Chuo-ku, Tokyo, Japannobelpharma.co.jp ↗
- Ownership
- Private
- Employees
- ~349
- Development stage
- Commercial
01
Overview
Nobelpharma has successfully developed and commercialized multiple products including NOBELZIN for Wilson's disease, HYFTOR (sirolimus topical gel) for facial angiofibroma associated with TSC, LUNABELL for dysmenorrhea, Melatobel for sleep onset improvement, Fostoin for status epilepticus, Gliadel for malignant glioma, Alabel for visualizing malignant glioma during surgery, and Unitalc for malignant pleural effusion[1][3][6].
- Therapeutic areas
- Metabolic DisordersDermatologyWomen's HealthOncologyRare DiseasesNeurology
- Modalities
- Small moleculestopical formulations
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Pfizer Inc.Novatech SAEsteve Pharmaceuticals SASNippon Shinyaku Co., Ltd.Fuji Pharma Co., Ltd.TSC Alliance
Beyond the preview
Go deeper on Nobelpharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nobelpharma Co., Ltd..